Treatment with fixed-dos combination sofosbuvir/velpatasvir yielded significant improvements in patient-reported outcomes.
The prevalence of HPV infection in US females aged 14-19 is approximately 25% and in females aged 20-24 it is increased to approximately 45%. Despite this high risk, in 2013, only 38% of females aged 13-17 have received all three recommended HPV vaccine doses.
Researchers identify limited evidence base and uneven clinical application as probable reasons for variation.
Bilateral disease is rare but may be caused by several drug classes. Physicians need to consider these medications and other etiologies in their differential diagnosis to ensure prompt and appropriate treatment.
As outlined by the authors, use of metformin is an appealing option because it is safe, produces few side effects, and is a cost-effective way to target some of the defects known to contribute to the metabolic defects associated with diabetes.
Teriflunomide was an effective first-line therapy for RRMS and a suitable switch therapy in real-world data.
We compared the incidence of late clinical events after withdrawal of clopidogrel between subjects treated with drug-eluting stents (DES) and those treated with bare-metal stents. Death and myocardial infarction occurred more frequently among DES-treated subjects during the follow-up period. The results of this study indicate that there may be a penalty for the lower rate of restenosis and reinterventions after DES implantation, in particular, an increased rate of late stent thromboses.
As the field of medical ethics continues to expand, its use can be seen in everything from general medical conditions to end of life considerations.
Some families can be demanding, some questioning, some "overly concerned," but how often do we discount what they are saying because of the way they communicate with us?
“We ought to learn as much as we can about what makes these persons unique so we can find more therapeutic options that can be expanded to a larger population.”
A review of the guidelines published by the American Headache Society and the American Academy of Neurology (AAN) in the April 2012 issue of Neurology reveals some interesting surprises.
The health and economic costs of poor lifestyle choices, poor health care planning, and misaligned incentives for care are the themes this week.
Determining the best way to identify patients statewide or nationally is one of the hottest topics of debate within today's health IT community.
The soon-to-be marketed therapy Dsuvia has shown enough benefit, tolerability, and safety to aid an at-need patient population in a controlled setting.